| Document |
Document Title |
|
WO/2003/024922A1 |
A hydroxyfattysulfonic acid analog represented by Formula (I): wherein X is an ethylene group, a vinylene group or an ethynylene group; Y is an ethylene group, a vinylene group, an ethynylene group, OCH¿2? or S(O)pCH¿2? wherein p is 0,...
|
|
WO/2003/020691A1 |
The invention relates to the alkalimetal salts, tetraalkyl ammonium salts and phosphonium salts of heptafluoro-2-propane sulfonates, said salts being suitable for use in electronic technology, for example as support electrolytes for batt...
|
|
WO/2003/020684A1 |
The present invention describes immobilized haloenamine reagents, immobilized tertiary amides, methods for their preparation, and methods of use.
|
|
WO/2003/018535A2 |
The invention relates to a novel class of aminobenzophenones derivatives, to pharmaceutical preparations comprising said compounds, to dosage units of such preparations, to methods of treating patients comprising administering said compo...
|
|
WO/2003/018552A2 |
The present invention is directed to protected amino acid halide monomers and oligomers, and to their use in the efficient sythesis of polyamides. The present invention is further directed to the use of -haloenamine reagents, which may o...
|
|
WO/2003/016254A1 |
Carboxylic acid derivatives represented by the following general formula (I) and nontoxic salts thereof: (I) wherein R1 represents COOH, COOR4 (wherein R4 represents alkyl, etc.), etc.&semi A represents alkylene, etc.&semi R2 represents ...
|
|
WO/2003/016249A1 |
A process for producing branched olefins from a mixed linear olefin/paraffin isomerisation feed comprising linear olefins having at least 7 carbon atoms in 5-50%w comprising in a first stage skeletally isomerising linear olefins in the i...
|
|
WO/2003/014070A1 |
This invention relates new and improved processes for the preparation of arylalkylsulfonic acids derived from aromatic or substituted aromatic molecules and AOS acid (generally a mixture of alkenesulfonic acid and sultones, produced from...
|
|
WO/2003/014056A1 |
A process for efficiently producing an optically active 2−bromocarboxylic acid and optically active 2−sulfonyloxycarboxylic acid which are important for producing medicines, etc. An optically active 2−sulfonyloxycarboxylic ester is...
|
|
WO2002030860A9 |
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders c...
|
|
WO/2003/014296A2 |
Compounds containing a specific saturated or unsaturated branched chain terminal group; a polar leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, substituted or unsubstituted, hydrocarbon group linking them...
|
|
WO/2003/010128A2 |
Perfluoroalkyl-substituted amines, acids, amino acids and thioether acid compounds containing a perfluoroalkyl-iodoalkyl or perfluoroalkyl-alkene group as well as derivatives thereof, are described. They are useful as surfactants in a va...
|
|
WO/2003/007933A1 |
Provided are napthoquinone-type compounds which can be used to modulate the aggregation of protein (e.g. tau) associated with neurodegenerative disease (e.g. Alzheimer's disease). Structure-function characteristics for oxidised and reduc...
|
|
WO/2003/006563A1 |
An imaging composition comprising a mixture of a fluid and a functional material; wherein the fluid is compressed and the functional material is dispersed and/or solubilized in the compressed fluid; and wherein the mixture is thermodynam...
|
|
WO/2003/004462A1 |
The invention relates to the sulfonyl esters of the general formula R¿1?-COO-SO¿2?-Z-R¿2?, wherein Z, R¿1? and R¿2? are defined as in claim 1. The invention further relates to the use of one of the inventive compounds for modifying ...
|
|
WO/2003/002157A1 |
The present invention relates to novel solid-phase processes for the production of radiolabelled tracers, in particular for the production of ?18¿F-labelled compounds which may be suitable for use as Positron Emission Tomography (PET) r...
|
|
WO/2003/002506A1 |
A process for producing a fluorinated vinyl ether through a simple procedure in high yield from a fluorinated acid fluoride compound having an ester group, which is a precursor for a carboxy group, or an SO2F group, which is a precursor ...
|
|
WO/2003/002514A1 |
The present invention relates to novel antidiabetic compounds, their derivatives, their analogs and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel 3-aryl propanoic acid...
|
|
WO/2002/102336A1 |
The invention relates to an agent for colouring fibres (A). Said agent is produced by mixing two constituents (A1) and (A2), and is characterised in that the constituent (A1) contains at least one quinonimine derivative of formula (I), a...
|
|
WO/2002/102765A2 |
The compound O-(2-[?18¿F]fluoroethyl)-L-tyrosine has proven to be particularly suitable for positron emission tomography and has already been tested in clinical practice. Until now, the compound has been produced according to a relative...
|
|
WO2002082185B1 |
A photoacid compound having general structure: R-O(CF2)nSO3X wherein n is an integer between about 1 to 4; R is selected from the group consisting of: substituted or unsubstituted C1-C12 linear or branched alkyl or alkenyl, substituted o...
|
|
WO/2002/100812A1 |
A medicine containing as the active ingredient a novel carboxylic acid derivative useful as an insulin resistance ameliorant. The carboxylic acid derivative is represented by the following general formula (I). Also provided are a salt or...
|
|
WO/2002/100870A1 |
Novel napsylate salts of formula I, or solvates of said salt, and stereoisomers thereof, as well as a process for the preparation thereof, pharmaceutical compositions containing the therapeutically active napsylate salt and the use of sa...
|
|
WO/2002/100869A1 |
Novel napsylate salts of formula I, or a solvate thereof, (I) and stereoisomers thereof, as well as a process for the preparation thereof, pharmaceutical compositions containing the therapeutically active napsylate salt and the use of sa...
|
|
WO/2002/098844A1 |
The invention relates to a method for producing perfluoroalkanesulfonic acid esters and for further transforming the same into the salts thereof. The invention also relates to the use of the produced compounds in electrolytes, batteries,...
|
|
WO/2002/098870A1 |
New oxime sulfonate compounds of the formula (I) and (II), wherein R¿1? is C¿1-?C¿12?alkyl, C¿1?-C¿4?haloalkyl, hydrogen, OR¿9?, NR¿10?R¿11?, SR¿12? or is phenyl which is unsubstituted or substituted by OH, C¿1?-C¿18?alkyl, ha...
|
|
WO/2002/096865A1 |
A process for the preparation of a compound of formula (I) in which R represents H or an acid protecting group which comprises reacting a compound of formula (II) in which R is as previously def ined with a compound of formula (III) wher...
|
|
WO/2002/092737A1 |
Surfactant mixtures, improved detergent and cleaning products containing particular types of alkybenzene sulfonate surfactants.
|
|
WO/2002/092600A1 |
This invention relates to novel compounds, capable of potentiating the efficacy of therapeutically active compounds, for example cytotoxic compounds used in the treatment of cancer. The novel compounds have been shown to increase the pha...
|
|
WO/2002/090297A1 |
A process that can be used for sulfonating, sulfating, or sulfamating an organic compound is disclosed. The process can comprise, consist essentially of, or consist of, contacting the organic compound with sulfur trioxide under a conditi...
|
|
WO/2002/090306A1 |
This invention relates to a process for the production of the cyclic ketone (1R,5S)-bicyclo[3.2.0]heptan-3-one. This compound is useful inter alia as an intermediate for the synthesis of analogues of gabapentin (Neurontin®). The reactio...
|
|
WO/2002/088072A1 |
The invention provides an industrially advantageous process for preparation of 3-methoxydecanol derivatives, specifically a process for preparation of compounds represented by the general formula (5), salts thereof, or hydrates of both, ...
|
|
WO/2002/088061A1 |
A novel compound which is highly effective in ameliorating the cellular disorders caused by radicals and in inhibiting the neurotoxicity induced by excitatory neurotransmitters such as glutamic acid. It is a compound represented by the f...
|
|
WO/2002/087725A1 |
A method for reducing malodors in hydrotropes, such as alkyl aryl sulfonates, is provided that reduces and/or eliminates some or all of the detectable residual odoriferous compounds from hydrotropic compositions using a malodor treatment...
|
|
WO/2002/085845A2 |
The invention relates to complex mixtures of sulfogroup-containing esters of polybasic organic acids with long-chain alkanols, alkoxyalkanols and diols, especially viscous oils obtained from oxosynthesis. The invention also relates to th...
|
|
WO/2002/083612A1 |
A process for producing (S)-1-(4-phenoxyphenoxy)-2-propanol having a high optical purity, characterized by reacting a sulfonic ester compound represented by the formula (1): (1) (wherein R?1¿ represents halogeno, nitro, or C¿1-4? alkyl...
|
|
WO/2002/081431A1 |
The invention relates to a method for preparing sulphinic perfluoroalkane acid salts. The inventive method is characterised in that it comprises at least one step involving the reaction of least one perfluoroalkyl halide having formula R...
|
|
WO/2002/081081A1 |
The invention relates to a composition comprising at least one amine-containing compound and ammonium bifluoride, the use thereof as a fluorinating agent and a method for preparing perfluoroalkanesulphonyl fluoride using said fluorinatin...
|
|
WO/2002/079158A1 |
Amlodipine camsylate of the present invention is a crystalline salt of amlodipine suitable for pharmaceutical formulation, which is prepared by using low toxic camphor sulfonic acid to meet required pharmaceutical properties for treating...
|
|
WO/2002/078693A2 |
The present invention provides compounds of formula (I), which are antagonists of the 5-HT¿6? receptor.
|
|
WO/2002/076930A2 |
Substituted diarylureas, pharmaceutical compositions containing them, and their use for stimulating Fas-mediated apoptosis. The compounds, as single stereoisomers or mixtures of stereoisomers, their pharmaceutically acceptable salts, and...
|
|
WO/2002/076939A2 |
Compounds having quinone and quinone analogs useful for pharmaceutical preparations have now been found which inhibit cysteine proteases, in particular, caspases and 3C-cysteine proteases. The cysteine protease inhibitors of the present ...
|
|
WO/2002/076931A1 |
A novel salt, creatine taurinate, and the compositions containing same (health foods, dietary supplements or drugs) are disclosed.
|
|
WO/2002/076375A2 |
The present invention relates to an improved process for the preparation of trifluoromethanesulfonic ester of ethyl (R)-2-hydroxy-4-phenylbutyrate, referred to here as triflate in structural Formula I, and to the use of this compound as ...
|
|
WO/2002/074735A2 |
Novel compounds of formula (I), where X, Y, Z, R, R?1¿, R?2¿ and R?3¿ have the meanings given in claim 1 are inhibitors of the coagulation factor Xa and may be used for prophylaxis and/or therapy of thromboembolitic diseases and for t...
|
|
WO/2002/074834A1 |
A process for producing a partially esterified SIPA such as an alkali metal sulfoisophthalic acid in a glycol is disclosed. The partially esterified SIPA in a glycol can be used to copolymerize with oligomer of terephthalic acid dimethyl...
|
|
WO/2002/074833A1 |
The present invention relates to an electrically conductive polymer, and more particularly to an additive for enhancing electrical conductivity of the polymer and electrically conductive polymer compositions containing the additive. The ...
|
|
WO/2002/072068A2 |
This invention pertains to certain lipids and lipid compositions, liposomes and lipoplexes formed therefrom, methods for their synthesis and preparation, compositions and medicaments comprising such liposomes and lipoplexes, and methods ...
|
|
WO/2002/072020A2 |
Compounds which exhibit anti-adhesive properties are described. The compounds may be monomers or polymers. Methods for treating receptor mediated diseases are provided using compounds of the invention. Further methods are provided for cr...
|
|
WO/2002/068504A1 |
The invention relates to addition compounds of formula (1) in which: n is a number from 1 to 10; Z represents a group -CH¿2?-CH¿2?-, -CH¿2?-CH(CH¿3?)-, -CH(CH¿3?)-CH¿2?- or a combination thereof; s is number from 1 to 200; B repres...
|
